News

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series!

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

In case you missed it, this week we had news on the FDA's breakthrough designation of litifilimab for CLE, data on bitopertin in EPP treatment, the role of icotrokinra in the psoriasis landscape, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

Kyowa Kirin takes full control of rocatinlimab, aiming to address unmet needs in atopic dermatitis while ensuring continuity in clinical trials.

Dermatology Times is looking back on the top stories in dermatology from the month of January.

Icotrokinra emerges as a groundbreaking oral treatment for moderate-to-severe psoriasis, showing superior efficacy compared to existing therapies at Maui Derm 2026.

Jennelle Daly, PA-C, explores the integration of aesthetic dermatology and wellness, emphasizing holistic approaches for optimal skin health and patient outcomes.

Explore the top headlines of the month, including insights on regulatory updates, expert pearls, and more.

A phase 2 trial reveals soficitinib's potential to significantly improve symptoms and quality of life in patients with moderate to severe AD.

Galderma addresses menopause-related skin changes at IMCAS 2026, revealing survey insights and committing to inclusive clinical trials for better patient solutions.

Learn more about the in-depth topics covered in the January 2026 print issue of Dermatology Times.

Galderma's Bill Andriopoulos, PhD, discusses Dysport's real-world success and evolving trends in aesthetic injectables, emphasizing patient satisfaction and innovative treatments.

Dermatology Times is recapping our exclusive expert interviews from the month of January.

Explore the nuanced experiences of drainage in hidradenitis suppurativa (HS), revealing its profound physical and psychological impacts on patients' lives.

James Del Rosso, DO, discusses innovative therapies for chronic hand eczema (CHE), chronic spontaneous urticaria (CSU), and vitiligo.

Discover insights from Bill Andriopoulos, PhD, on Relfydess, a groundbreaking neuromodulator utilizing PEARL Technology for enhanced efficacy and safety.

Explore the importance of HEV blue light protection, especially post-procedures, and discover effective patient strategies for managing melasma and skin health.

Explore the nuances of off-label dermatology therapies, emphasizing evidence-based practices, patient communication, and ethical considerations for optimal care.

Innovative acne treatments emerge, including sponge-derived therapies and microbiome strategies, promising a brighter future for patients.

The FDA’s decision was based on litifilimab’s phase 2 skin disease activity data.

This review of the latest vitiligo studies includes insights on the efficacy of ritlecitinib, the risk of herpes zoster, oxidative stress in red blood cells for this patient population, and more.

Ritlecitinib shows promising facial repigmentation in vitiligo patients, with consistent efficacy across diverse demographics in a phase 2b study.

Karen McGuire, PhD, discusses TolaSure, a groundbreaking therapy targeting epidermolysis bullosa simplex, focusing on cellular repair and blister reduction.

Litifilimab shows significant efficacy in improving skin outcomes for CLE, as demonstrated in the phase 2 LILAC study.

Explore the potential of glucagon-like peptide-1 (GLP-1) therapies in dermatology, including inflammatory skin diseases such as psoriasis and hidradenitis suppurativa, to improve patient outcomes.

Jennelle Daly, MPAS, PA-C, reveals essential winter sunscreen insights, emphasizing UVA risks and patient education for effective photoprotection against melanoma.

Aclaris Therapeutics' ATI-2138 shows promising rapid hair regrowth in severe alopecia areata models, highlighting its potential as a novel treatment option.

Obagi and Alpha Aesthetic Partners will collaborate on the ALOHA Program, enhancing real-world evidence for the innovative saypha MagIQ hyaluronic acid filler.

Christopher Bunick, MD, PhD, led a vital discussion on innovative vitiligo treatments, emphasizing combination therapies and psychosocial support for effective management.